Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. Additionally we are shipping Somatostatin Receptor 2 Antibodies (56) and Somatostatin Receptor 2 Kits (8) and many more products for this protein.
Showing 6 out of 7 products:
Somatostatin (show SST Proteins) directly promoted spontaneous contractions of the circular muscle of macaque intestine via mediation of SSTR2 in myenteric nerve plexus between the longitudinal and the circular muscle.
5-HT(1A (show HTR1A Proteins)), SST (show SST Proteins)(1), and SST (show SST Proteins)(2) receptors mediate nonadrenergic IPSPs in the noncholinergic (VIP (show Vip Proteins)) secretomotor neurons of the submucous plexus of the guinea pig ileum.
Filamin-A (show FLNA Proteins) is required to mediate SSTR2 effects in pancreatic neuroendocrine tumours
Data showed that the distribution of somatostatin (show SST Proteins) receptor (SSTR (show SSTR3 Proteins)) subtypes among the 199 pancreatic neuroendocrine tumors (PNETs) was: SSTR2 (54.8%), SSTR1 (show SSTR1 Proteins) (53.3%), SSTR4 (51.8%), SSTR5 (show SSTR5 Proteins) (33.7%), and SSTR3 (show SSTR3 Proteins) (28.6%).
SSTR2 promoter hypermethylation might be associated with the risk and progression of laryngeal squamous cell carcinoma in males.
VPA was observed to stimulate the expression of somatostatin receptor type 2 (SSTR2).
Results show that histological subtyping of pituitary tumor correlated with SSTR2, E cadherin (show CDH1 Proteins) and p27kip protein levels and these may serve as useful biomarkers for prognosis.
there is an elevation in CXCR4 (show CXCR4 Proteins) and a decrease in SSTR2A expression with increasing malignancy in gastroenteropancreatic neuroendocrine neoplasms
mir (show MLXIP Proteins)-185 regulates the expression of SSTR2 in GH-secreting pituitary adenoma. The staining intensity of SSTR2 is stronger in adenoma samples than controls.
Data indicate that somatostatin (show SST Proteins) receptor scintigraphy (SRS (show SMS Proteins)) and immunohistochemical results for somatostatin (show SST Proteins) and dopamine receptors sstr2, sstr3 (show SSTR3 Proteins), sstr5 (show SSTR5 Proteins) and D2R (show DRD2 Proteins) were compared in neuroendocrine neoplasms tissues.
CD56 (show NCAM1 Proteins) marker is a useful alternative that is comparable to SSTR2A for the diagnosis of phosphaturic mesenchymal tumors.
The number of SSTR-2-expressing cells was significantly smaller in the patients with Crohn's disease than that in those with the unchanged mucosa and in those with indeterminate (unclassified) colitis.
Loss of sst2 from pancreatic tissues activates PI3K signaling via AKT (show AKT1 Proteins), leading to activation of NF-kappaB (show NFKB1 Proteins), amplification of oncogenic KRAS signaling, increased expression of CXCL16 (show CXCL16 Proteins), and pancreatic tumor formation.
The expression and localization of the three receptors (SSTR3 (show SSTR3 Proteins)-SSTR5 (show SSTR5 Proteins)) in wild-type (WT), single-knockout (SSTR1 (show SSTR1 Proteins) KO) and double-knockout SSTR1 (show SSTR1 Proteins)/SSTR2 (DKO) mice, are reported.
SST2 expression protects against gentamicin-induced auditory hair cell loss in the mammalian inner ear.
Knock-down of SSTR2 leads to loss of pluripotency in murine embryonic stem cells.
Inhibition of the Sstr2 receptor reversed the anticonvulsant effect mediated by cortistatin-14 (show CORT Proteins).
OCT-P407 induces mRNA expression of SSTR-2 and caspase-3 and decreases that of VEGF in mice.
The study encourages the use of liver tissue SSR2 (show SSR2 Proteins) protein and mRNA as a reliable tumor marker for liver cancer
when activated by SST (show SST Proteins)-14, SSTR2A internalizes and recycles via the Golgi, which requires ECE-1 (show ECE1 Proteins) degradation of SST (show SST Proteins)-14 and receptor dissociation from beta-arrestins
Findings suggest that somatostatin (show SST Proteins) and its receptors (SSTR2 and SSTR5 (show SSTR5 Proteins)) are important markers in the regulation and development of Sertoli cell.
The aim of this study was to validate an animal model expressing SSTR2 and to correlate the immunohistochemical (IHC) analysis with (18)F-FDG (show SMUG1 Proteins) and (68)Ga-DOTATOC uptake in vivo.
Follicle-stimulating hormone regulates the SSTR2 protein expression in bovine granulosa cells.
SRIF (show SST Proteins) can inhibit testosterone secretion through the sst2A receptor; local inhibitory action of SRIF (show SST Proteins) is probably autocrine & might involve testosterone-induced increase of sst2 receptor expression in immature Leydig cells [SST2A]
Data demonstrate that urotensin II (show UTS2 Proteins) and urotensin II-related peptide directly activate somatostatin (show SST Proteins) receptors 2 and 5 and thus mimic the effect of somatostatin (show SST Proteins) on its cognate receptors.
Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. The biologic effects of somatostatin are probably mediated by a family of G protein-coupled receptors that are expressed in a tissue-specific manner. SSTR2 is a member of the superfamily of receptors having seven transmembrane segments and is expressed in highest levels in cerebrum and kidney.
somatostatin receptor 2
, somatostatin type 2 receptor
, somatostatin receptor type 2
, somatostatin receptor type 2-like
, somatostatin receptor subtype 2
, somatotropin release-inhibiting factor receptor